Polymerase chain reaction (PCR)-based testing of cerebrospinal fluid (CSF) specimens has become standard for confirmatory diagnosis of central nervous system (CNS) infections; however, these tests increase health care costs. We reviewed 3-year data from 974 consecutive CSF specimens submitted for detection of seven pathogens by PCR. In 1997, 237 of 367 specimens (64.6%) were submitted for multiple tests, compared with 203 of 522 (38.9%) in 1996 and 18 of 85 (21.2%) in 1995. In each year the arrival of new house officers coincided with a peak in multiple testing. Among 732 specimens submitted for herpesvirus detection, results were positive for 24 (4.6%) of 523 specimens with increased leukocyte counts or protein levels. None of 209 specimens with normal leukocyte and protein levels were positive for herpesviruses. None of 471 CSF specimens submitted for Borrelia burgdorferi detection were PCR-positive. Use of protein and leukocytes to screen CSF specimens before employing PCR for herpesvirus detection would save almost one-third of costs without reducing sensitivity.
Conventional methods remain inadequate for the laboratory diagnosis of many CNS infections. PCR performed on CSF is recognized as the new "gold standard" for some of these infections [1] [2] [3] [4] [5] . However, with implementation of these new assays, there is a tendency to request multiple tests in an effort to obtain at least one positive result.
Decreasing costs while maintaining quality has become an essential role of the clinical laboratory and physician services alike. This requires continuous evaluation of the value of all "routine" diagnostic tests [6, 7] . Physicians control Ͼ70% of health care expenditures; therefore, efficient selection of critical laboratory tests by physicians has significant impact on total medical costs [6, 8] . Clinicians at the Mayo Clinic can request PCR tests of CSF on a standard laboratory request form that lists seven pathogens, including herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicellazoster virus (VZV), JC virus (JCV), Borrelia burgdorferi, and Tropheryma whippelii. The cumulative fee for these assays, several of which are usually ordered simultaneously, is Ͼ$1,200.00 (United States currency), of which 9%-15% goes directly toward PCR patent royalties. The vast majority of these tests yield negative results.
CSF leukocyte counts and total protein levels are predictive of CNS infections [2, 9, 10] . In the present study, we evaluated these inexpensive, routine determinations for their ability to predict the outcome of more expensive PCR-based testing.
Methods
All CSF specimens from Mayo Clinic patients submitted for molecular testing between 1 January 1995 and 31 December 1997 were analyzed for this study. Specimens were tested in accordance with clinician requests; no tests were performed except those ordered by the clinical service submitting the specimen. Clinical information on these patients, including indications for testing, clinical diagnoses, other testing performed, treatment, and response, was not available for this analysis. An abnormal CSF total protein level was defined as Ͼ45 mg/dL, while an abnormal CSF leukocyte count was defined as Ͼ5 nucleated cells/mm 3 . PCR-based methods for detection of HSV, CMV, EBV, VZV, JCV, B. burgdorferi, and T. whippelii have been published elsewhere and were not altered during the study period [4, [11] [12] [13] [14] [15] . The 2 values for trends, odds ratios, and confidence limits were calculated with use of Epi Info, version 6.04b (Centers for Disease Control and Prevention, Atlanta).
Results
During a period of 3 years, a total of 16,125 CSF specimens were processed in the Molecular Microbiology Diagnostic Laboratory for PCR testing. We identified 974 specimens (6.0%) that were collected from Mayo Clinic patients, of which 24 (2.5%) were positive for one pathogen and 2 (0.2%) were positive for two pathogens. ) (figure 1). Figure 2 shows that in the third quarter, when new house officers arrived, 167 of 303 specimens (55.1%) were submitted for multiple tests, compared with 291 of 671 (43.4%) submitted the rest of the year (OR, 6.7; 95% CI, 1.2-2.1). This tendency remained the same each year (data not shown).
Among 732 specimens submitted for detection of herpesvirus (HSV, CMV, EBV, and/or VZV), results were positive for 24 of 523 (4.6%) with abnormal leukocyte counts or total protein levels (table 2). In contrast, none of 209 specimens with normal leukocyte and protein levels were positive for herpesviruses (OR, 0.0; 95% CI, 0.0 -0.4). Furthermore, specimens in which both leukocyte counts and protein levels were abnormal had a higher diagnostic yield of herpesviruses than did samples in which only one of these indicators was positive (18 of There were too few positive results to demonstrate whether CSF leukocyte and protein levels were associated with positive test results for JCV or T. whippelii (table 2) . None of 471 CSF specimens submitted for B. burgdorferi detection were PCRpositive, although 322 (68.4%) had abnormal leukocyte counts or protein levels (table 2). Among the 471 specimens submitted, only 143 (30.4%) were from patients who had undergone Lyme serological tests previously. Fifteen (3.2%) of 471 patients tested for neuroborreliosis had indeterminate serological status, and five (1.1%) were serologically reactive.
Discussion
Our data indicate that the elimination of PCR testing of CSF specimens with normal leukocyte and protein levels would save almost one-third of costs associated with herpesvirus testing, without decreasing sensitivity. Significant improvement in patient care might result if expensive workups following false-positive results, common in PCR-based tests, can be avoided. Accordingly, we recommend that specimens with normal leukocyte and protein levels should be rejected for herpesvirus PCR testing, except in special circumstances (e.g., leukopenia or a recommendation by neurology or infectious disease consultants).
Our data demonstrated a significant trend toward multiple testing of specimens that provided little clinically useful information. An interesting finding was that multiple tests occurred more frequently in the third quarter of each year, when new residents and fellows start clinical training. Our results are similar to those of McGillivray et al., who showed increased laboratory usage in the third quarter and by less experienced physicians [16] . These data reinforce the importance of edu- cating medical professionals to use PCR tests in a costeffective manner, particularly for diagnosis of CNS infections.
HSV is of special importance among organisms for which we offer PCR testing. PCR is proven to have high sensitivity for detection of HSV DNA in CSF specimens [4, 5] . It is the only one of these tests whose results may lead to proven lifesaving therapy [17, 18] , although therapeutic protocols do exist for the other pathogens. HSV was also the most frequently detected pathogen in our study, and none of 13 HSVpositive patients were found to have any other CSF pathogens. We therefore suggest that when HSV PCR is ordered in combination with other CSF PCR tests, the HSV PCR should be performed first, before the other assays.
Our study indicated that multiple PCR tests are requested frequently when order forms list the assays in a menu format. While multiple tests may be indicated for some patients, we suggest that menu-driven requests for multiple PCR assays engender low-yield secondary tests of limited diagnostic value. The use of PCR-test-request forms that list assays for only the most prevalent pathogens with the strongest indications for therapy (HSV, in our study) might reduce redundant testing while preserving the option to order tests for specific pathogens on an ad hoc basis.
Both serology and PCR tests have been used for diagnosis of Lyme neuroborreliosis [19 -21] . Our data suggest that PCR of CSF is unsuitable as a screening test for the diagnosis of Lyme neuroborreliosis, even when CSF abnormalities are present. Studies have found that B. burgdorferi can invade the CNS early in the course of infection, but for patients with illness of Ͼ1 month's duration, serological testing is almost always positive [19 -22] . Since objective neurological deficits generally appear later in the course of B. burgdorferi infection, serological testing for Lyme disease should be used to screen appropriate candidates for PCR testing, which in our experience was highly specific but very expensive.
We feel that PCR testing of seronegative patients is not appropriate, except when the examination is performed early in the course of disease on patients with a compatible history, including suitable exposure risk factors.
Among patients positive for non-HSV herpesviruses, 2 (14.3%) were positive for both EBV and VZV. While we wish to discourage indiscriminate use of PCR on CSF specimens, there are clearly subpopulations in which multiple testing will be appropriate as therapy improves. Our current strategy of using singleorganism PCR is not an economically viable means of coping with this task. In the future, multiplex PCR or automated assays may be used to detect panels of probable pathogens at a reasonable cost [23, 24] . For the present, however, we encourage clinicians to use inexpensive screening tests prior to PCR testing and then to prioritize tests in order of likelihood. 
